BASED UP ON SYMPTOMS TO PREVENT PSORIASIS AND PSORIATIC ARTHRITIS

Authors

  • Kattepogu Naga Kumari Assistant Professor, Department of Pharmaceutical Sciences, Hindu College of Pharmacy
  • Shaik Shakeela Hindu College of Pharmacy, Guntur-522002, Andhra Pradesh, India
  • CH Ramya Hindu College of Pharmacy, Guntur, Andhra Pradesh, India – 522002
  • Jyothirmai Namathoti Hindu College of Pharmacy, Guntur, Andhra Pradesh, India – 522002

Keywords:

Psoriatic Arthritis is chronic inflammatory diseases of the joints where tendons and ligaments connect to bone. In this article, learn about treatment and prevention strategies for psoriatic arthritis.

Abstract

The present study indicates that the Psoriatic arthritis (PsA) is chronic, inflammatory diseases of the joints and enthuses, where tendons and ligaments connect to the bone. It can start at any age and may affect children. The diseases often appear between ages 30 and 50. In this article, learn about treatment and prevention strategies for psoriatic arthritis, as well as the risk factors for developing it. Also, because a small number of people develop psoriatic arthritis without skin symptoms of psoriasis, it can be difficult to identify everyone who is at risk. Also, because a small number of people develop psoriatic arthritis without skin symptoms of psoriasis, it can be difficult to identify everyone who is at risk. The researchers found that, after 1 year of treatment, psoriatic arthritis was in remission in 58% of the people with the disease, compared with 44% of the people with rheumatoid arthritis. A 2019 medical review article Trusted Source highlights the many challenges that doctor’s face in trying to prevent psoriatic arthritis. Doctors do not fully understand how or why the disease progresses or who is at risk. More research could, one day, answer these questions. For now, controlling the symptoms of psoriasis before it progresses into arthritis may help reduce the severity of both diseases. Who develop psoriatic arthritis, the right treatment can minimize disease activity.

References

I. Freedberg, Irwin M.; Fitzpatrick, Thomas B. Fitzpatrick's dermatology in general medicine pp. 427–436. (6th ed.) (2003).

II. James, William; Berger, Timothy; Elston, Dirk Andrews' Diseases of the Skin: Clinical Dermatology Saunders. p. 194. (10th ed.). (2005).

III. Amherd-Hoekstra A, Näher H, Lorenz HM, Enk AH 8 (5): 332,(May 2010).

IV. Papadakis, Maxine A. McPhee, Stephen J., eds.. (2023).

V. Psoriatic Arthritis". Arthritis Action. Archived from the original on Retrieved 12 August 2015. 27 January 2016.

VI. Davidson, Stanley, Davidson's principles and practice of medicine, Churchill Livingstone,Elsevier, p. 1096, 11-12, 2010. 2016.

VII. Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP "Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies". Ann. Rheum. Dis. 62 (5): 664–75. (May 2010).

VIII. Gottlieb, Alice; Korman, Neil J.; Gordon, Kenneth B.; Feldman, Steven R.; Lebwohl,. Retrieved 2011-05-04. 58 (5) (May 2008).

IX. Singh, Jasvinder A.; Guyatt, Gordon; Ogdie, Alexis; Gladman, Dafna D.; Deal, Chad; Deodhar, Atul; Dubreuil, Maureen; Dunham, Jonathan; Husni, M. Elaine; Kenny, Sarah; Retrieved. 71 (1) Jan 2019, 2018. 5 December 2020, 2021-04-06

X. "Infectious risks associated with biologics". Hot Topics in Infection and Immunity in Children IX. Adv. Exp. Med. Biol. Advances in Experimental Medicine and Biology. Vol. 764. pp. 151–8 (2013).

XI. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999). "Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis". (13): 7563–. J. Med. 80 (4B): 34, April 1986.

XII. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA Mar Circulation. 115 (12): 1634, 2007.

XIII. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C "Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials".1302,(Jun 2006).

XIV. Jones, Graeme; Crotty, Maria; Brooks, Peter "Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis". The Cochrane Database of Systematic Reviews. 2010 (4), (2000-07-24) 2000 (3),(2019-01-18) 2019, Jan 1; 58(1), P (19 October 2005).

XV. The Johns Hopkins University School of Medicine and the Johns Hopkins Arthritis Center. Retrieved 2011-05-04.

XVI. Who's At Risk, Be Joint Smart (a coalition of the National Psoriasis Foundation and the Arthritis Foundation). Accessed 2016-11-12.

XVII. Ogdie, Alexis; Merola, Joseph F, Ritchlin, Christopher "Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition". Nature Reviews Rheumatology. 15 (3): 153–166. (March 2019).

XVIII. "Psoriatic Arthritis". WebMD LLC. Retrieved 2011-05-04.

XIX. Ritchlin, Christopher T.; Colbert, Robert A.; Gladman, Dafna D. "Psoriatic Arthritis". 376 (10): 957–970. (2017-03-08).

Additional Files

Published

15-06-2023

How to Cite

Kattepogu Naga Kumari, Shaik Shakeela, CH Ramya, & Jyothirmai Namathoti. (2023). BASED UP ON SYMPTOMS TO PREVENT PSORIASIS AND PSORIATIC ARTHRITIS. International Education and Research Journal (IERJ), 9(6). Retrieved from http://ierj.in/journal/index.php/ierj/article/view/2767